Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parallel Review: End Of Phase II Could Be Best Time For CMS Involvement

Executive Summary

Assuming FDA and CMS move forward with their plan to start parallel reviews of medical products, the end of Phase II trials may be the best time for CMS to start having input in the clinical development process for drugs, a CMS official suggested.
Advertisement

Related Content

FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both
CMS/FDA Parallel Review: Agencies Weighing Process For Planning Trials That Satisfy Both

Topics

Advertisement
UsernamePublicRestriction

Register

PS052967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel